Drug intelligence / Profile preview

ganoderma lucidum

Development stage
Phase 3
Lead developer
Revive Therapeutics
Administration
Oral
01

Overview

Ganoderma lucidum is a medicinal mushroom used as an orally administered natural product, dietary supplement, and nutraceutical rather than a single defined pharmaceutical active ingredient. Clinical and translational literature in the provided sources describes multiple preparations of this organism, including whole mushroom powder, aqueous extract, spore powder, wall-removed spore powder, and triterpene- or polysaccharide-containing extracts, studied across overweight, metabolic, neurologic, allergic, and oncology supportive-care settings. Its proposed pharmacology is pleiotropic and incompletely defined, with reported immunomodulatory, anti-inflammatory, metabolic, and potential antitumor effects attributed mainly to polysaccharides such as beta-glucans, triterpenes including ganoderic acids, and other fungal constituents; published mechanistic work in the provided context mentions modulation of gut microbiota, AMP-activated protein kinase signaling, NF-kappaB-related pathways, microglial activation, and iNOS/NLRP3-associated neuroinflammatory signaling. Because the exact chemical composition and mechanism depend strongly on the specific preparation, \"ganoderma lucidum\" is best treated as a nonspecific botanical or fungal drug substance family rather than a single molecular entity.

Brand names
Ganopoly
Other names
lingzhireishi mushroom
02

Targets

PTPN1 (Protein tyrosine phosphatase 1B)LFA-1 (Integrin αLβ2)TLR (Toll-like receptors)CLEC7A (Dectin-1)

Beyond the preview

Go deeper on ganoderma lucidum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganoderma lucidum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call